These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24441502)

  • 1. Vaccination therapy for non-small-cell lung cancer.
    Cuppens K; Vansteenkiste J
    Curr Opin Oncol; 2014 Mar; 26(2):165-70. PubMed ID: 24441502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for lung cancer: ongoing clinical trials.
    Declerck S; Vansteenkiste J
    Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
    Adam V; Wauters I; Vansteenkiste J
    Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
    Tyagi P; Mirakhur B
    Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
    Perez CA; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
    Mellstedt H; Vansteenkiste J; Thatcher N
    Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
    Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
    Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
    Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.